Fulgent Genetics, Inc. reported $324M of revenue over the trailing twelve months, +6.8% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $324M (to Q2 2026). Net income: −$84M, trailing twelve months to Q2 2026. Free cash flow: −$104M, trailing twelve months to Q2 2026. Operating margin: −38%, trailing twelve months to Q2 2026.

FLGTFulgent Genetics, Inc.

Healthcare

$20.87-7.8% 1Y

$20.87

$13.7952 weeks$30.85

FLGT as reported

Fulgent Genetics, Inc. reported $324M of revenue over the trailing twelve months, +6.8% on the year before. 11 reported series are charted on this page, each one as filed.

$324M

Revenue, trailing twelve months · to Q2 2026 · +6.8% against the twelve months before

Net income: −$84M
Net income · +65% year on year · trailing twelve months to Q2 2026
Free cash flow: −$104M
Free cash flow · +73% year on year · trailing twelve months to Q2 2026
Operating margin: −38%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for FLGT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$324M	+6.8%	Q2 2026
Net income	−$84M	+65%	Q2 2026
EPS	−$2.82	+70%	Q2 2026
Gross margin	35%	n/a	Q2 2026
Operating margin	−38%	n/a	Q2 2026
Net margin	−26%	n/a	Q2 2026
ROE	−6.2%	n/a	Q2 2026
ROA	−5.7%	n/a	Q2 2026
ROIC	−9.7%	n/a	Q2 2026
Free cash flow	−$104M	+73%	Q2 2026
P/E	4.87	n/a	Q4 2022 · 14 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.